Latest available resultsQuarter ended June 30, 202610-Q · August 6, 2026
Filed with the SECGILEAD SCIENCES, INC.
GILDPharma & biotech
Next reportOctober 28, 2026Analyst forecast 2.191 $/share
Revenue
$7.80B
▲ +10.2% vs prior year% YoY
Net income
−$10.50B
▼ -635.5% vs prior year% YoY
EPS
-8.45$
▼ -641.7% vs prior year% YoY
Net margin
-134.5%
▼ -162.2 percentage points vs prior year pp YoY
Revenue▲ +10.2 %
Margins (% of revenue)GrossOperatingNet
Net income▼ -635.5 %
EPS▼ -641.7 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $7.80B | |
| Gross profit | $6.22B | 79.8 % |
| Operating income | −$10.39B | -133.2 % |
| Net income | −$10.50B | -134.5 % |
| R&D | — | |
| EPS (diluted) | -8.45 $ | |
| Balance sheet | ||
| Assets | $49.36B | |
| Liabilities | $37.62B | |
| Equity | $11.74B | |
| Cash | — | |
| Capital | ||
| Shares outstanding | 1.24B | as of 2026-07-31 |
| Public float | — | |